Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegAsp BID vs IDegAsp QD + IAsp BID in Type 2 Diabetes Mellitus
NCT05417841Completed
- Sponsor
- Beijing Hospital
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Glycated Hemoglobin at 16 weeks. Started Mar 2023; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05417841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417841.